Grand Pharmaceutical Group Ltd
HKEX:512
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.21
9.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Grand Pharmaceutical Group Ltd stock under the Base Case scenario is 6.55 HKD. Compared to the current market price of 8.08 HKD, Grand Pharmaceutical Group Ltd is Overvalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Grand Pharmaceutical Group Ltd.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Grand Pharmaceutical Group Ltd
Balance Sheet Decomposition
Grand Pharmaceutical Group Ltd
| Current Assets | 8B |
| Cash & Short-Term Investments | 1.4B |
| Receivables | 4.6B |
| Other Current Assets | 1.9B |
| Non-Current Assets | 18.4B |
| Long-Term Investments | 8.3B |
| PP&E | 4.4B |
| Intangibles | 4.5B |
| Other Non-Current Assets | 1.2B |
| Current Liabilities | 6.7B |
| Accounts Payable | 5.2B |
| Accrued Liabilities | 2B |
| Short-Term Debt | 2.3m |
| Other Current Liabilities | -495.5m |
| Non-Current Liabilities | 2.6B |
| Long-Term Debt | 1.8B |
| Other Non-Current Liabilities | 794.8m |
Free Cash Flow Analysis
Grand Pharmaceutical Group Ltd
| HKD | |
| Free Cash Flow | HKD |
Earnings Waterfall
Grand Pharmaceutical Group Ltd
|
Revenue
|
11.7B
HKD
|
|
Cost of Revenue
|
-5B
HKD
|
|
Gross Profit
|
6.7B
HKD
|
|
Operating Expenses
|
-4.8B
HKD
|
|
Operating Income
|
2B
HKD
|
|
Other Expenses
|
103.8m
HKD
|
|
Net Income
|
2.1B
HKD
|
Profitability Score
Profitability Due Diligence
Grand Pharmaceutical Group Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Grand Pharmaceutical Group Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Grand Pharmaceutical Group Ltd's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Grand Pharmaceutical Group Ltd's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Grand Pharmaceutical Group Ltd
According to Wall Street analysts, the average 1-year price target for Grand Pharmaceutical Group Ltd is 12.09 HKD with a low forecast of 11.82 HKD and a high forecast of 12.6 HKD.
Dividends
Current shareholder yield for Grand Pharmaceutical Group Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one Grand Pharmaceutical Group Ltd stock under the Base Case scenario is 6.55 HKD.
Compared to the current market price of 8.08 HKD, Grand Pharmaceutical Group Ltd is Overvalued by 19%.